Answers are grounded in this paper and cite their sources.
Sepsis, a life-threatening organ dysfunction triggered by a dysregulated host response to infection, represents a formidable global health crisis, exacerbated by the relentless rise of multidrug-resistant (MDR) bacteria. Antibiotic treatment is increasingly challenged by antimicrobial resistance, and conventional monoclonal antibody (mAb) therapies face significant manufacturing and logistical hurdles. This review focuses on the use of messenger RNA (mRNA) as a programmable platform to turn the patient's own body into a bioreactor for producing therapeutic antibodies on demand. We explore the transformative potential of this strategy, which merges the precision of antibody therapy with the speed and flexibility of nucleic acid technology. We critically analyze the ground-breaking preclinical evidence for mRNA-encoded antibodies against key bacterial virulence factors, such as the Pseudomonas aeruginosa Type III secretion system (T3SS). Beyond direct pathogen neutralization, we propose a visionary dual-pronged approach, combining anti-pathogen mRNA with immunomodulatory strategies to simultaneously control infection and rebalance the dangerously chaotic immune response characteristic of sepsis. However, the path to clinical reality is fraught with challenges, including targeted delivery to systemic infection sites, the dearth of long-term safety data, and the absence of a mature regulatory framework. We conclude by outlining a roadmap for the future, envisioning an era of multiplexed, personalized mRNA cocktails and artificial intelligence (AI)-driven design, which could finally provide a potent and adaptable weapon in the war against superbug sepsis and multi-organ failure.
No takes yet. Share an insight, caveat, or question.
Pei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: